- Home
- XGN vs ATRA Comparison
XGN vs ATRA Comparison
Compare XGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- ATRA
- Stock Information
- Founded
- XGN 2002
- ATRA 2012
- Country
- XGN United States
- ATRA United States
- Employees
- XGN N/A
- ATRA N/A
- Industry
- XGN Medical Specialities
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XGN Health Care
- ATRA Health Care
- Exchange
- XGN Nasdaq
- ATRA Nasdaq
- Market Cap
- XGN 138.3M
- ATRA 40.1M
- IPO Year
- XGN 2019
- ATRA 2014
- Fundamental
- Price
- XGN $7.00
- ATRA $8.04
- Analyst Decision
- XGN Strong Buy
- ATRA Buy
- Analyst Count
- XGN 2
- ATRA 5
- Target Price
- XGN $7.50
- ATRA $17.75
- AVG Volume (30 Days)
- XGN 237.8K
- ATRA 48.4K
- Earning Date
- XGN 08-04-2025
- ATRA 08-11-2025
- Dividend Yield
- XGN N/A
- ATRA N/A
- EPS Growth
- XGN N/A
- ATRA N/A
- EPS
- XGN N/A
- ATRA N/A
- Revenue
- XGN $56,724,000.00
- ATRA $199,732,000.00
- Revenue This Year
- XGN $19.39
- ATRA N/A
- Revenue Next Year
- XGN $13.27
- ATRA N/A
- P/E Ratio
- XGN N/A
- ATRA N/A
- Revenue Growth
- XGN 1.78
- ATRA 475.53
- 52 Week Low
- XGN $1.71
- ATRA $5.01
- 52 Week High
- XGN $7.95
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- XGN 52.23
- ATRA 48.89
- Support Level
- XGN $6.62
- ATRA $7.51
- Resistance Level
- XGN $7.35
- ATRA $8.25
- Average True Range (ATR)
- XGN 0.48
- ATRA 0.53
- MACD
- XGN -0.10
- ATRA -0.13
- Stochastic Oscillator
- XGN 29.63
- ATRA 20.25
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).